About FLC
- Free Light Chains (FLCs) are immunoglobulin light chains which are circulating in serum in a free state (unbound). There are two types of immunoglobulin light chain produced in humans, designated kappa (κ) and lambda (λ).
- The quantification of serum FLC is used as an aid in the diagnosis and monitoring patients with Multiple Myeloma.
- Ratio FLC value (kappa FLC/lambda FLC) compared to reference ranges may indicate presence of plasma cell disorders disease like Multiple Myeloma or AL amyloidosis in a patient.
- Nephelometric and turbidimetric based assays have been shown to overestimate the sFLC levels that are not always consistent with Serum Protein Electrophoresis/Immunofixation and other clinical parameters.
Key benefits
Reliable and high analytical performance results
with correct estimation of FLC values without antigen excess or overestimation by polymerization vs Nephelometry / Turbidimetry Methods.
Trust in the results
with concordance value between SPE and FLC Kappa & FLC Lambda which help on interpretation results.
Easy to implement
for patient therapy monitoring and meeting IMWG guidelines.
4 times lower retest rates
vs other methods and lower manual dilutions needed.
Easily adapted and scalable
to any type of ELISA Instrument for standardization and efficiency process.
Main characteristics
Quantification of Kappa or Lambda Free Light Chains is performed with an Enzyme-Linked Immunosorbent Assay (ELISA) procedure utilizing specific antibodies anti-Kappa or anti-Lambda free light chains.
Serum sample
Microplate with 96 wells in strip format.
- FLC Kappa – P/N: 5102
- FLC Lambda – P/N: 5103
- FLC Control Level 1 – P/N: 5112
- FLC Control Level 2 – P/N: 5113
Related resources
See all resourcesComplete your Myeloma diagnostic tools with Sebia FLC Assay
The serum Free Light Chains is an important test in Prognosis and Monitoring of Multiple Myeloma patients.
Apr. 11, 2022 Nov. 20, 2024
IFCC Euromedlab 2021
Sebia booth: #121
Sebia Workshop: EduW22
Multiple Myeloma clinical cases for diagnosis and monitoring according to latest IMWG recommendations
Educational Webinar with Prof. Alessandro Gozzetti, MD, PhD
Jun. 27, 2022 Jun. 29, 2022
IFCC Worldlab 2022
Sebia booth: #72
Sebia Workshop: EduW25
AL Amyloidosis: Role of clinical lab in diagnosis and management
Educational Webinar with Prof. Giovanni PALLADINI, PhD
May. 22, 2023 May. 24, 2023
IFCC Euromedlab /WorldLab 2023
Sebia booth: #21
Sebia Workshop: EduW15
Clinical use of FLC testing in Multiple Myeloma and AL Amyloidosis
Educational Workshop with Pr Giovanni Palladini
Current Status of Detecting Monoclonal Antibodies and Free Light Chains in Serum
Educational Webinar with Dr. Matthias Orth from University of Heidelberg at University Hospital Mannheim.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Sebia receives U.S. FDA Clearance for the FLC Kappa & Lambda assays
Expanding offering for Multiple Myeloma and AL Amyloidosis Testing.
Apr. 18, 2024 Apr. 20, 2024
European Myeloma Network Meeting – EMN 2024
Sebia booth: #9
Timely Diagnosis of Myeloma in Populations with Comorbidities and Health Disparities: Testing Considerations
Educational Webinar with Dr. Joseph Mikhael MD and Dr. Christopher Farnsworth, PhD
Scientific publications
See all publicationsMultiple Myeloma: « 20 » and « 100 » Ratios Cut-off applicable to Sebia FLC assays
The « 20 » and « 100 » Ratios Cut-off can be used in routine with Sebia FLC assays for high-risk smoldering multiple myeloma stratification and for assessing progression to active multiple myeloma or amyloidosis.
* based on the IMWG Criteria for the Diagnosis of MM
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.